Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor

Rhea-AI Summary

Enochian BioSciences (NASDAQ: ENOB) appointed Dr. Richard Whitley, M.D., as its Senior Scientific Advisor. With a robust background in virology and extensive experience in developing antiviral therapies, Dr. Whitley aims to contribute significantly to Enochian's research endeavors. CEO Dr. Mark Dybul emphasized the importance of Dr. Whitley’s expertise in advancing the company's research pipelines, particularly the innovative “Hijack” RNA approach. Dr. Whitley's accolades include multiple publications and significant contributions during the COVID-19 pandemic.

Positive

• Appointment of Dr. Richard Whitley as Senior Scientific Advisor expected to strengthen research capabilities.
• Dr. Whitley brings extensive virology experience and published over 347 articles, enhancing credibility.
• Focus on innovative 'Hijack' RNA approach could lead to promising antiviral therapies.

Negative

• None.

LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company’s Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies.

"We are incredibly excited to bring on Dr. Whitley as a Senior Scientific Advisor," said Enochian's CEO Dr. Mark Dybul. "Rich is not only a talented clinician, but also a well noted researcher whose experience and expertise will be instrumental in our research pipelines. Rich's eagerness to transition to this role is further evidence that key members of the scientific community continue to place trust in Enochian and that the Company is committed to advancing its potential products to commercialization, which could save millions of lives from deadly illnesses."

"I'm excited to take on this new role at Enochian, a company built on using innovative approaches to potentially curing or putting into remission some of the world's most devastating diseases," said Dr. Whitley. "As a clinician and researcher in viruses for many years, I am particularly excited about the Company's "Hijack" RNA approach, which has the potential to be a promising platform to save countless lives. I look forward to helping the Company advance its most promising therapies to human studies."

In addition to his pediatrics professorship at UAB, Dr. Whitley is also the Loeb Eminent Scholar Chair in Pediatrics, the Co-Director of the Division of Pediatric Infectious Diseases, a Senior Scientist in the Department of Gene Therapy, and a Senior Advisor for Drug Discovery and Development. Beyond his work at UAB, Dr. Whitley has published more than 347 articles, and he actively participates on several Data Safety and Monitoring Boards for ongoing clinical studies. During the COVID-19 pandemic, he worked as a project director on a National Institute of Allergy and Infectious Diseases-funded grant that evaluated the efficacy of the antiviral medication remdesivir in COVID patients. This year, Dr. Whitley was awarded the American Pediatric Society's highest honor, the John Howland Award.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Media Contact: enob@hamiltonps.com

Source: Enochian Biosciences

FAQ

What is the significance of Dr. Richard Whitley's appointment at Enochian BioSciences?

Dr. Richard Whitley’s appointment as Senior Scientific Advisor is significant due to his extensive experience in virology and antiviral therapies, which may enhance the company's research capabilities.

How can Dr. Whitley's expertise benefit Enochian BioSciences?

Dr. Whitley's expertise can benefit Enochian BioSciences by guiding the development of its research pipelines, particularly through innovative technologies like the 'Hijack' RNA approach.

What are Dr. Whitley's qualifications related to virology?

Dr. Whitley is a Distinguished Professor of Pediatrics, has published over 347 articles on virology, and has significant clinical research experience in developing antiviral therapies.

What is Enochian BioSciences' focus area in antiviral research?

Enochian BioSciences focuses on innovative approaches to develop antiviral therapies, particularly through their 'Hijack' RNA technology.

What recognition has Dr. Whitley received in his career?

Dr. Whitley received the John Howland Award, the highest honor from the American Pediatric Society, highlighting his contributions to pediatrics and infectious diseases.